|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Progress in renewable energy 显示文摘 | Gross Robert Leach Matthew Bauen Ausilio | 2003 | Environment International2003，29，1： | 1 |
| 2 | Progress in renewable energy显示文摘 | Robert Gross Matthew Leach Ausilio Bauen | 2002 | Environment International2002，，1： | 1 |
| 3 | Demand response experience in Europe: Policies, programmes and implementation显示文摘 | Jacopo Torriti Mohamed G. Hassan Matthew Leach | 2009 | Energy2009，，4： | 1 |
| 4 | Progress in renewable energy显示文摘 | Robert Gross Matthew Leach Ausilio Bauen | 2002 | Environment International2002，，1： | 1 |
| 5 | Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial显示文摘 | Dow-Mu Koh Matthew Blackledge David J. Collins Anwar R. Padhani Toni Wallace Benjamin Wilton N. Jane Taylor J. James Stirling Rajesh Sinha Pat Walicke Martin O. Leach Ian Judson Paul Nathan | 2009 | European Radiology2009，，： | 1 |
| 6 | A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance显示文摘 | Dharminder Chauhan Ze Tian Benjamin Nicholson K.G. Suresh Kumar Bin Zhou Ruben Carrasco Jeffrey L. McDermott Craig A. Leach Mariaterresa Fulcinniti Matthew P. Kodrasov Joseph Weinstock William D. Kingsbury Teru Hideshima Parantu K. Shah Stephane Minvielle | 2012 | Cancer Cell2012，，3： | 1 |
| 7 | Progress in renewable energy显示文摘 | Leach Matthew Bauen Ausilio | 2003 | Environment International2003，29，1： | 1 |
| 8 | Demand response experience in Europe:Policies,programs and implementation显示文摘 | Jacopo Torriti Mohamed G Hassan Matthew Leach | | 0，，35： | 1 |
| 9 | Progress in renewable energy 显示文摘 | Gross Robert Leach Matthew Bauen Ausilio | 2003 | Environment International2003，29，1： | 1 |
| 10 | Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer显示文摘 | Paul Nathan Martin Zweifel Anwar R. Padhani Dow-Mu Koh Matthew Ng David J. Collins Adrian Harris Craig Carden Jon Smythe Nita Fisher N. Jane Taylor J. James Stirling Shiao-Ping Lu Martin O. Leach Gordon J.S. Rustin Ian Judson | 2012 | Clinical Cancer Research2012，，： | 1 |
| 11 | The effectiveness and safety of ginger for pregnancy-induced nausea and vomiting: A systematic review显示文摘 | Mingshuang Ding Matthew Leach Helen Bradley | 2012 | Women and Birth2012，，： | 1 |
| 12 | Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial显示文摘 | Dow-Mu Koh Matthew Blackledge David J. Collins Anwar R. Padhani Toni Wallace Benjamin Wilton N. Jane Taylor J. James Stirling Rajesh Sinha Pat Walicke Martin O. Leach Ian Judson Paul Nathan | 2009 | European Radiology2009，，11： | 1 |
| 13 | Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome显示文摘BACKGROUND Individuals with Lynch syndrome(LS)and hereditary non-polyposis colorectal cancer(HNPCC)are at increased risk of both colorectal cancer and other cancers.The interplay between immunosuppression,a comorbid inflammatory condition(CID),and HNPCC on cancer risk is unclear.AIM To evaluate the impact of CIDs,and exposure to monoclonal antibodies and immunomodulators,on cancer risk in individuals with HNPCC.METHODS Individuals prospectively followed in a hereditary cancer registry with LS/HNPCC with the diagnosis of inflammatory bowel disease or rheumatic disease were identified.We compared the proportion of patients with cancer in LS/HNPCC group with and without a CID.We also compared the proportion of patients who developed cancer following a CID diagnosis based upon exposure to immunosuppressive medications.RESULTS A total of 21 patients with LS/HNPCC and a CID were compared to 43 patients with LS/HNPCC but no CID.Cancer occurred in 84.2% with a CID compared to 76.7% without a CID(P=0.74)with no difference in age at first cancer diagnosis 45.5±14.6 vs 43.8±7.1 years(P=0.67).LS specific cancers were diagnosed in 52.4% with a CID vs 44.2% without a CID(P=0.54).Nine of 21(42.9%)patients were exposed to biologics or immunomodulators for the treatment of their CID.Cancer after diagnosis of CID was seen in 7(77.8%)of exposed individuals vs 5(41.7%)individuals unexposed to biologics/immunomodulators(P=0.18).All 7 exposed compared to 3/5 unexposed developed a LS specific cancer.The exposed and unexposed groups were followed for a median 10 years and 8.5 years,respectively.The hazard ratio for cancer with medication exposure was 1.59(P=0.43,95%CI:0.5-5.1).CONCLUSION In patients with LS/HNPCC,the presence of a concurrent inflammatory condition,or use of immunosuppressive medication to treat the inflammatory condition,might not increase the rate of cancer occurrence in this limited study. | Muhammad S Faisal Carol A Burke David Liska Amy L Lightner Brandie Leach Margaret O’Malley Lisa LaGuardia Benjamin Click JP Achkar Matthew Kalady JM Church Gautam Mankaney | 2022 | World Journal of Clinical Oncology2022，13，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员